Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 1, Pages 90-93Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyp117
Keywords
cervical cancer; palliative chemotherapy; recurrent; persistent; Stage IVB; cisplatin; carboplatin; paclitaxel
Categories
Funding
- The Ministry of Health, Labour and Welfare of Japan
Ask authors/readers for more resources
A randomized controlled trial has been started in Japan to compare the utility of palliative chemotherapy containing paclitaxel and carboplatin (TC) with paclitaxel and cisplatin (TP) as a standard treatment for patients with the newly diagnosed Stage IVB, persistent or recurrent cervical cancer who are not amenable to curative treatment with local therapy. This trial was designed to evaluate the non-inferiority of TC as measured by the number of hospitalized days as an indicator of quality of life (QOL) when compared with TP combination therapy. The primary endpoint is overall survival. Secondary endpoints are progression-free survival, response rates, adverse events, severe adverse events and the proportion of non-hospitalization periods compared with planned treatment periods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available